Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of
patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0109. 2009 Indexing Status Subject indexing assigned by CRD MeSH Aged; Antineoplastic Combined Chemotherapy Protocols; Melphalan; Multiple Myelomas; Prednisone; Thalidomide Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000418 Date abstract record published 08/08/2012 |